Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PTCT – PTC Therapeutics Inc

PTC Therapeutics, Inc.
PTCT
$52.13
Name : PTC Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,131,667,456.00
EPSttm : 6.51
finviz dynamic chart for PTCT
PTC Therapeutics, Inc.
$52.13
0.04%
$0.02

Float Short %

7.62

Margin Of Safety %

34

Put/Call OI Ratio

0.39

EPS Next Q Diff

-10.79

EPS Last/This Y

12.46

EPS This/Next Y

-10.41

Price

52.13

Target Price

67.38

Analyst Recom

1.88

Performance Q

5.27

Relative Volume

0.8

Beta

0.54

Ticker: PTCT




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04PTCT49.070.3612.006166
2025-07-07PTCT47.940.370.226178
2025-07-08PTCT47.650.340.147023
2025-07-09PTCT48.740.340.417050
2025-07-10PTCT49.520.350.317208
2025-07-11PTCT48.580.330.098996
2025-07-14PTCT49.420.330.079031
2025-07-15PTCT47.760.281.2211076
2025-07-16PTCT48.120.300.0311297
2025-07-17PTCT48.540.303.1211521
2025-07-18PTCT47.620.350.2912131
2025-07-21PTCT47.880.310.0211368
2025-07-22PTCT46.380.301.0611631
2025-07-23PTCT47.110.380.0113734
2025-07-24PTCT46.480.320.0315866
2025-07-25PTCT44.690.303.5216945
2025-07-28PTCT44.340.400.0518963
2025-07-29PTCT49.30.310.6223944
2025-07-30PTCT50.950.430.0629771
2025-07-31PTCT52.130.390.1632434
2025-08-01PTCT52.090.390.0232896
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04PTCT49.076.0155.17.56
2025-07-07PTCT47.956.0119.67.56
2025-07-08PTCT47.656.0145.87.56
2025-07-09PTCT48.746.0196.87.56
2025-07-10PTCT49.526.0184.47.56
2025-07-11PTCT48.556.0151.07.56
2025-07-14PTCT49.466.0189.17.56
2025-07-15PTCT47.756.0100.37.56
2025-07-16PTCT48.136.0171.27.56
2025-07-17PTCT48.536.0171.57.56
2025-07-18PTCT47.626.0126.17.56
2025-07-21PTCT47.876.0166.57.56
2025-07-22PTCT46.366.0104.37.56
2025-07-23PTCT47.086.0183.57.56
2025-07-24PTCT46.326.0129.87.56
2025-07-25PTCT44.7416.298.17.57
2025-07-28PTCT44.3616.2142.27.57
2025-07-29PTCT49.2916.2360.47.57
2025-07-30PTCT50.9416.2213.27.57
2025-07-31PTCT52.1116.2209.87.57
2025-08-01PTCT52.1316.3172.67.73
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04PTCT-6.911.816.58
2025-07-07PTCT-6.911.786.58
2025-07-08PTCT-6.911.786.58
2025-07-09PTCT-6.911.786.58
2025-07-10PTCT-6.911.786.58
2025-07-11PTCT-6.101.787.77
2025-07-14PTCT-6.101.947.77
2025-07-15PTCT-6.101.947.77
2025-07-16PTCT-6.101.947.77
2025-07-17PTCT-6.101.947.77
2025-07-18PTCT-6.201.947.77
2025-07-21PTCT-6.202.617.77
2025-07-22PTCT-6.202.617.92
2025-07-23PTCT-3.822.617.92
2025-07-24PTCT-3.822.617.92
2025-07-25PTCT-3.822.617.62
2025-07-28PTCT-3.822.427.62
2025-07-29PTCT-3.822.427.62
2025-07-30PTCT-3.822.427.62
2025-07-31PTCT-3.822.427.62
2025-08-01PTCT-3.822.427.62
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

10.04

Avg. EPS Est. Current Quarter

-1.19

Avg. EPS Est. Next Quarter

-0.75

Insider Transactions

-3.82

Institutional Transactions

2.42

Beta

0.54

Average Sales Estimate Current Quarter

173

Average Sales Estimate Next Quarter

194

Fair Value

69.73

Quality Score

94

Growth Score

42

Sentiment Score

97

Actual DrawDown %

26.4

Max Drawdown 5-Year %

-73.8

Target Price

67.38

P/E

8.01

Forward P/E

PEG

P/S

2.33

P/B

P/Free Cash Flow

5.96

EPS

6.51

Average EPS Est. Cur. Y​

7.73

EPS Next Y. (Est.)

-2.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

33.55

Relative Volume

0.8

Return on Equity vs Sector %

-344

Return on Equity vs Industry %

-325.3

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.28

EBIT Estimation

172.6
PTC Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 939
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
stock quote shares PTCT – PTC Therapeutics Inc Stock Price stock today
news today PTCT – PTC Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTCT – PTC Therapeutics Inc yahoo finance google finance
stock history PTCT – PTC Therapeutics Inc invest stock market
stock prices PTCT premarket after hours
ticker PTCT fair value insiders trading